Market Cap 12.09B
Revenue (ttm) 1.16B
Net Income (ttm) 168.11M
EPS (ttm) N/A
PE Ratio 46.88
Forward PE 45.43
Profit Margin 14.50%
Debt to Equity Ratio 0.14
Volume 990,900
Avg Vol 868,042
Day's Range N/A - N/A
Shares Out 158.89M
Stochastic %K 57%
Beta 1.27
Analysts Strong Sell
Price Target $85.00

Latest News on TECH

ScaleReady awards a G-Rex® Grant to Moonlight Bio

Dec 18, 2024, 7:00 AM EST - 4 weeks ago

ScaleReady awards a G-Rex® Grant to Moonlight Bio


BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY

Dec 10, 2024, 7:00 AM EST - 5 weeks ago

BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY


BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES

Nov 8, 2024, 7:00 AM EST - 2 months ago

BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES


Bio-Techne Corporation (TECH) Q1 2025 Earnings Call Transcript

Oct 30, 2024, 3:48 PM EDT - 2 months ago

Bio-Techne Corporation (TECH) Q1 2025 Earnings Call Transcript


BIO-TECHNE DECLARES DIVIDEND

Oct 30, 2024, 6:30 AM EDT - 2 months ago

BIO-TECHNE DECLARES DIVIDEND


BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS

Oct 30, 2024, 6:30 AM EDT - 2 months ago

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS


BIO-TECHNE ISSUES 2024 CORPORATE SUSTAINABILITY REPORT

Sep 18, 2024, 7:00 AM EDT - 4 months ago

BIO-TECHNE ISSUES 2024 CORPORATE SUSTAINABILITY REPORT


Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant

Sep 17, 2024, 7:00 AM EDT - 4 months ago

Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant


BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES

Aug 26, 2024, 7:00 AM EDT - 5 months ago

BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES


BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS

Aug 7, 2024, 6:30 AM EDT - 5 months ago

BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS


BIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO

Jul 29, 2024, 7:00 AM EDT - 6 months ago

BIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO


BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES

May 31, 2024, 7:00 AM EDT - 8 months ago

BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES